BLC USA

BLC USA is dedicated to developing early-stage projects through clinical trials focused on antimicrobial resistance (AMR). The company collaborates with partners to address the growing threat of AMR, recognizing the urgent need for new antibiotics as current options are limited and the market for treating gram-negative infections is substantial. BLC USA emphasizes the critical importance of accelerating the discovery and development of new treatments to combat antimicrobial resistance.